Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events

1 Jan 2019

Abstract excerpt

Unprecedented successes regarding cancer immunotherapy have been achieved, in which therapeutic agents are used to target immune cells rather than cancer cells. The most effective immunotherapy to date is the group of immune checkpoint inhibitors (CPI), targeting, for example, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death protein (PD-1). TThe combination of these therapies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31423333
DOI: 10.1136/esmoopen-2018-000472

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse eventsPMID 31423333Read ↗

Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity Read ↗

Germline genetic variation and predicting immune checkpoint inhibitor induced toxicitySemantic proximity Read ↗

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition TherapySemantic proximity Read ↗

Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitorsSemantic proximity Read ↗

Germline mechanisms of immunotherapy toxicities in the era of genome‐wide association studiesSemantic proximity Read ↗

The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity Read ↗

Crossroads between autoimmunity and cancer: underlying mechanisms and clinical implications.Semantic proximity Read ↗

Association between programmed death protein 1-related single-nucleotide polymorphisms and immune-related adverse events induced by programmed death protein 1 inhibitors-a pilot study.Semantic proximity Read ↗

Autoimmunity and Cancer—Two Sides of the Same CoinSemantic proximity Read ↗

Bridging clinical phenotypes with molecular mechanisms in autoimmune irAEs: An Etiopathogenic framework.Semantic proximity Read ↗

Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint BlockadeSemantic proximity Read ↗

Association of Blood Biomarkers and Autoimmunity with Immune Related Adverse Events in Patients with Cancer treated with Immune Checkpoint InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.